Real-world study: early vs delayed start with TRELEGY after first exacerbation

Real-world study: early vs delayed start with TRELEGY after first exacerbation

hero dots
dots-mobile

Can an earlier start with TRELEGY after a COPD exacerbation affect patient outcomes?1

Can an earlier start with TRELEGY after a COPD exacerbation affect patient outcomes?1

A retrospective cohort study evaluated the impact of early vs delayed TRELEGY initiation in patients after their first COPD exacerbation.1

See results from IMPACT, a landmark trial of 10,000+ patients with a history of at least 1 COPD exacerbation.

In a retrospective cohort study of patients after their first COPD exacerbation

Early start with TRELEGY associated with reduction in exacerbations1


Primary outcome: rate of moderate to severe exacerbations1

Results are descriptive only.

TRELEGY Results for Moderate to Severe Exacerbations Bar Graph
TRELEGY Results for Moderate to Severe Exacerbations Bar Graph

In a retrospective cohort study of patients after their first COPD exacerbation

Early start with TRELEGY associated with reduction in hospitalized exacerbations1


Primary outcome: rate of severe (hospitalized) exacerbations1

Results are descriptive only.

TRELEGY Results for Severe Exacerbations Bar Graph
TRELEGY Results for Severe Exacerbations Bar Graph

Primary outcome: rate of moderate exacerbations per person-year: delayed TRELEGY initiation (n=1375), 1.03; early TRELEGY initiation (n=529), 0.86; 16% reduction, RR (95% CI): 0.84 (0.69, 0.99).1

Exacerbation severity criteria: moderate if outpatient or emergency department visit with a primary COPD exacerbation diagnosis code and ≥1 dispensing or administration of a systemic corticosteroid or guideline-recommended antibiotic within 5 days of visit; severe if hospitalization with a primary COPD exacerbation diagnosis code.1

  • Real-world study description and considerations1

    Study description: A retrospective cohort study used IQVIA data in primarily commercially insured patients to evaluate early (0-30 days) vs delayed (31-180 days) TRELEGY initiation after their first COPD exacerbation. A total of 1904 patients ≥40 years of age (mean age: 60 years) were included. At first exacerbation, 82% of patients had a moderate exacerbation and 18% had a severe (hospitalized) exacerbation. Select inhaled maintenance treatments used any time during the 12-month baseline period included ICS/LABA (41%), LAMA (20%), and LAMA/LABA (14%). This study did not exclude patients with an asthma diagnosis code. However, patients with asthma were not included in TRELEGY COPD clinical trials.

    Important study considerations:

    • Real-world studies are designed to evaluate associations among variables and not to definitively establish causality.
    • Results are limited to the patient population studied, which differs from patient populations in randomized controlled trials, and may not be generalizable to the wider US patient population.
    • Differences exist in patient populations and data collection vs randomized controlled trials. Findings may not be generalizable to uninsured or other insured US populations.

In a retrospective cohort study of patients after their first COPD exacerbation

Early start with TRELEGY associated with extended time before next exacerbation1


Select secondary outcome: time to next moderate or severe COPD exacerbation1

Results are descriptive only.

TRELEGY Results for Extended Time to the Next Exacerbation Bar Graph
TRELEGY Results for Extended Time to the Next Exacerbation Bar Graph

At 12 months after first exacerbation, 49.8% of patients with early TRELEGY initiation (n=529) vs 59.4% with delayed TRELEGY initiation (n=1375) had an additional exacerbation, HR (95% CI): 0.72 (0.62, 0.83).1

  • Real-world study description and considerations1

    Study description: A retrospective cohort study used IQVIA data in primarily commercially insured patients to evaluate early (0-30 days) vs delayed (31-180 days) TRELEGY initiation after their first COPD exacerbation. A total of 1904 patients ≥40 years of age (mean age: 60 years) were included. At first exacerbation, 82% of patients had a moderate exacerbation and 18% had a severe (hospitalized) exacerbation. Select inhaled maintenance treatments used any time during the 12-month baseline period included ICS/LABA (41%), LAMA (20%), and LAMA/LABA (14%). This study did not exclude patients with an asthma diagnosis code. However, patients with asthma were not included in TRELEGY COPD clinical trials.

    Important study considerations:

    • Real-world studies are designed to evaluate associations among variables and not to definitively establish causality.
    • Results are limited to the patient population studied, which differs from patient populations in randomized controlled trials, and may not be generalizable to the wider US patient population.
    • Differences exist in patient populations and data collection vs randomized controlled trials. Findings may not be generalizable to uninsured or other insured US populations.
3 dots
cta-lungs

A previous study demonstrated that just 1 moderate or severe exacerbation can lead to a significant decline in lung function2

publish-icon

PUBLICATIONS WITH COPD EXACERBATION DATA

PUBLICATIONS WITH
COPD EXACERBATION DATA

IMPACT Clinical Trial

Real-world Study

 

What do experts say about triple therapy for COPD?

Play video

 

Help your patients try TRELEGY.

Help your patients
try TRELEGY.

Request samples now

 

Learn about COPD patients who may be appropriate for TRELEGY.

View profile

Want to see local coverage for TRELEGY vs other therapies?

Learn more